journal
https://read.qxmd.com/read/38649851/multiplex-proteomics-identifies-inflammation-related-plasma-biomarkers-for-aging-and-cardio-metabolic-disorders
#1
JOURNAL ARTICLE
Siting Wu, Yulin Li, Xue Zhao, Fu-Dong Shi, Jingshan Chen
BACKGROUND: Cardio-metabolic disorders (CMDs) are common in aging people and are pivotal risk factors for cardiovascular diseases (CVDs). Inflammation is involved in the pathogenesis of CVDs and aging, but the underlying inflammatory molecular phenotypes in CMDs and aging are still unknown. METHOD: We utilized multiple proteomics to detect 368 inflammatory proteins in the plasma of 30 subjects, including healthy young individuals, healthy elderly individuals, and elderly individuals with CMDs, by Proximity Extension Assay technology (PEA, O-link)...
April 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38594611/proteomics-study-of-primary-and-recurrent-adamantinomatous-craniopharyngiomas
#2
JOURNAL ARTICLE
Haidong Deng, Ting Lei, Siqi Liu, Wenzhe Hao, Mengqing Hu, Xin Xiang, Ling Ye, Dongting Chen, Yan Li, Fangjun Liu
BACKGROUND: Adamantinomatous craniopharyngiomas (ACPs) are rare benign epithelial tumours with high recurrence and poor prognosis. Biological differences between recurrent and primary ACPs that may be associated with disease recurrence and treatment have yet to be evaluated at the proteomic level. In this study, we aimed to determine the proteomic profiles of paired recurrent and primary ACP, gain biological insight into ACP recurrence, and identify potential targets for ACP treatment...
April 9, 2024: Clinical Proteomics
https://read.qxmd.com/read/38580967/plasma-proteomic-characterization-of-colorectal-cancer-patients-with-folfox-chemotherapy-by-integrated-proteomics-technology
#3
JOURNAL ARTICLE
Xi Wang, Keren Zhang, Wan He, Luobin Zhang, Biwei Gao, Ruijun Tian, Ruilian Xu
BACKGROUND: Colorectal Cancer (CRC) is a prevalent form of cancer, and the effectiveness of the main postoperative chemotherapy treatment, FOLFOX, varies among patients. In this study, we aimed to identify potential biomarkers for predicting the prognosis of CRC patients treated with FOLFOX through plasma proteomic characterization. METHODS: Using a fully integrated sample preparation technology SISPROT-based proteomics workflow, we achieved deep proteome coverage and trained a machine learning model from a discovery cohort of 90 CRC patients to differentiate FOLFOX-sensitive and FOLFOX-resistant patients...
April 5, 2024: Clinical Proteomics
https://read.qxmd.com/read/38580905/the-relationship-between-serum-astroglial-and-neuronal-markers-and-aqp4-and-mog-autoantibodies
#4
JOURNAL ARTICLE
Miyo K Chatanaka, Lisa M Avery, Maria D Pasic, Shanthan Sithravadivel, Dalia Rotstein, Catherine Demos, Rachel Cohen, Taron Gorham, Mingyue Wang, Martin Stengelin, Anu Mathew, George Sigal, Jacob Wohlstadter, Ioannis Prassas, Eleftherios P Diamandis
BACKGROUND: Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquaporin-4 (αAQP4) and myelin oligodendrocyte glycoprotein (αMOG). The variability of the autoantibody presentation warrants further research into subtyping each case. METHODS: To elucidate the relationship between astroglial and neuronal protein concentrations in the peripheral circulation with occurrence of these autoantibodies, 86 serum samples were analyzed using immunoassays...
April 5, 2024: Clinical Proteomics
https://read.qxmd.com/read/38565978/simultaneous-targeted-and-discovery-driven-clinical-proteotyping-using-hybrid-prm-dia
#5
JOURNAL ARTICLE
Sandra Goetze, Audrey van Drogen, Jonas B Albinus, Kyle L Fort, Tejas Gandhi, Damiano Robbiani, Véronique Laforte, Lukas Reiter, Mitchell P Levesque, Yue Xuan, Bernd Wollscheid
BACKGROUND: Clinical samples are irreplaceable, and their transformation into searchable and reusable digital biobanks is critical for conducting statistically empowered retrospective and integrative research studies. Currently, mainly data-independent acquisition strategies are employed to digitize clinical sample cohorts comprehensively. However, the sensitivity of DIA is limited, which is why selected marker candidates are often additionally measured targeted by parallel reaction monitoring...
April 2, 2024: Clinical Proteomics
https://read.qxmd.com/read/38549072/correction-proteomic-signature-associated-with-chronic-kidney-disease-ckd-progression-identified-by-data-independent-acquisition-mass-spectrometry
#6
Carlos R Ramírez Medina, Ibrahim Ali, Ivona Baricevic-Jones, Aghogho Odudu, Moin A Saleem, Anthony D Whetton, Philip A Kalra, Nophar Geifman
No abstract text is available yet for this article.
March 28, 2024: Clinical Proteomics
https://read.qxmd.com/read/38509475/quantitative-proteomic-analysis-of-her2-protein-expression-in-pdac-tumors
#7
LETTER
Jamie Randall, Allison L Hunt, Aratara Nutcharoen, Laura Johnston, Safae Chouraichi, Hongkun Wang, Arthur Winer, Raymond Wadlow, Jasmine Huynh, Justin Davis, Brian Corgiat, Nicholas W Bateman, John F Deeken, Emanuel F Petricoin, Thomas P Conrads, Timothy L Cannon
Metastatic pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a 5-year survival rate of only 11%, necessitating identification of novel treatment paradigms. Tumor tissue specimens from patients with PDAC, breast cancer, and other solid tumor malignancies were collected and tumor cells were enriched using laser microdissection (LMD). Reverse phase protein array (RPPA) analysis was performed on enriched tumor cell lysates to quantify a 32-protein/phosphoprotein biomarker panel comprising known anticancer drug targets and/or cancer-related total and phosphorylated proteins, including HER2Total , HER2Y1248 , and HER3Y1289 ...
March 20, 2024: Clinical Proteomics
https://read.qxmd.com/read/38481131/human-tear-film-protein-sampling-using-soft-contact-lenses
#8
JOURNAL ARTICLE
Robert K Roden, Nathan Zuniga, Joshua C Wright, David H Parkinson, Fangfang Jiang, Leena M Patil, Rebecca S Burlett, Alyssa A Nitz, Joshua J Rogers, Jarett T Pittman, Kenneth L Virgin, P Christine Ackroyd, Samuel H Payne, John C Price, Kenneth A Christensen
BACKGROUND: Human tear protein biomarkers are useful for detecting ocular and systemic diseases. Unfortunately, existing tear film sampling methods (Schirmer strip; SS and microcapillary tube; MCT) have significant drawbacks, such as pain, risk of injury, sampling difficulty, and proteomic disparities between methods. Here, we present an alternative tear protein sampling method using soft contact lenses (SCLs). RESULTS: We optimized the SCL protein sampling in vitro and performed in vivo studies in 6 subjects...
March 13, 2024: Clinical Proteomics
https://read.qxmd.com/read/38475715/neat-plasma-proteomics-getting-the-best-out-of-the-worst
#9
JOURNAL ARTICLE
Ines Metatla, Kevin Roger, Cerina Chhuon, Sara Ceccacci, Manuel Chapelle, Pierre-Olivier Schmit, Vadim Demichev, Ida Chiara Guerrera
Plasma proteomics holds immense potential for clinical research and biomarker discovery, serving as a non-invasive "liquid biopsy" for tissue sampling. Mass spectrometry (MS)-based proteomics, thanks to improvement in speed and robustness, emerges as an ideal technology for exploring the plasma proteome for its unbiased and highly specific protein identification and quantification. Despite its potential, plasma proteomics is still a challenge due to the vast dynamic range of protein abundance, hindering the detection of less abundant proteins...
March 12, 2024: Clinical Proteomics
https://read.qxmd.com/read/38475692/proteomics-of-prostate-cancer-serum-and-plasma-using-low-and-high-throughput-approaches
#10
JOURNAL ARTICLE
Ghaith M Hamza, Rekha Raghunathan, Stephanie Ashenden, Bairu Zhang, Eric Miele, Andrew F Jarnuczak
Despite progress, MS-based proteomics in biofluids, especially blood, faces challenges such as dynamic range and throughput limitations in biomarker and disease studies. In this work, we used cutting-edge proteomics technologies to construct label-based and label-free workflows, capable of quantifying approximately 2,000 proteins in biofluids. With 70µL of blood and a single depletion strategy, we conducted an analysis of a homogenous cohort (n = 32), comparing medium-grade prostate cancer patients (Gleason score: 7(3 + 4); TNM stage: T2cN0M0, stage IIB) to healthy donors...
March 12, 2024: Clinical Proteomics
https://read.qxmd.com/read/38454337/correction-to-using-phosphoproteomics-data-to-understand-cellular-signaling-a-comprehensive-guide-to-bioinformatics-resources
#11
Sara R Savage, Bing Zhang
No abstract text is available yet for this article.
March 7, 2024: Clinical Proteomics
https://read.qxmd.com/read/38429673/proteomic-analysis-of-plasma-proteins-from-patients-with-cardiac-rupture-after-acute-myocardial-infarction-using-tmt-based-quantitative-proteomics-approach
#12
JOURNAL ARTICLE
Jingyuan Hou, Qiaoting Deng, Xiaohong Qiu, Sudong Liu, Youqian Li, Changjing Huang, Xianfang Wang, Qunji Zhang, Xunwei Deng, Zhixiong Zhong, Wei Zhong
BACKGROUND: Cardiac rupture (CR) is a rare but catastrophic mechanical complication of acute myocardial infarction (AMI) that seriously threatens human health. However, the reliable biomarkers for clinical diagnosis and the underlying signaling pathways insights of CR has yet to be elucidated. METHODS: In the present study, a quantitative approach with tandem mass tag (TMT) labeling and liquid chromatography-tandem mass spectrometry was used to characterize the differential protein expression profiles of patients with CR...
March 1, 2024: Clinical Proteomics
https://read.qxmd.com/read/38429638/closing-the-gaps-in-patient-management-of-dyslipidemia-stepping-into-cardiovascular-precision-diagnostics-with-apolipoprotein-profiling
#13
REVIEW
Esther Reijnders, Arnoud van der Laarse, L Renee Ruhaak, Christa M Cobbaert
In persons with dyslipidemia, a high residual risk of cardiovascular disease remains despite lipid lowering therapy. Current cardiovascular risk prediction mainly focuses on low-density lipoprotein cholesterol (LDL-c) levels, neglecting other contributing risk factors. Moreover, the efficacy of LDL-c lowering by statins resulting in reduced cardiovascular risk is only partially effective. Secondly, from a metrological viewpoint LDL-c falls short as a reliable measurand. Both direct and calculated LDL-c tests produce inaccurate test results at the low end under aggressive lipid lowering therapy...
March 1, 2024: Clinical Proteomics
https://read.qxmd.com/read/38424522/proteomic-analysis-of-breast-cancer-based-on-immune-subtypes
#14
JOURNAL ARTICLE
Yeonjin Jeon, GunHee Lee, Hwangkyo Jeong, Gyungyub Gong, JiSun Kim, Kyunggon Kim, Jae Ho Jeong, Hee Jin Lee
BACKGROUND: Immunotherapy is applied to breast cancer to resolve the limitations of survival gain in existing treatment modalities. With immunotherapy, a tumor can be classified into immune-inflamed, excluded and desert based on the distribution of immune cells. We assessed the clinicopathological features, each subtype's prognostic value and differentially expressed proteins between immune subtypes. METHODS: Immune subtyping and proteomic analysis were performed on 56 breast cancer cases with neoadjuvant chemotherapy...
February 29, 2024: Clinical Proteomics
https://read.qxmd.com/read/38424496/highly-sensitive-therapeutic-drug-monitoring-of-infliximab-in-serum-by-targeted-mass-spectrometry-in-comparison-to-elisa-data
#15
JOURNAL ARTICLE
Andreas Hentschel, Gina Piontek, Rob Dahlmann, Peter Findeisen, Roman Sakson, Phil Carbow, Thomas Renné, Yvonne Reinders, Albert Sickmann
BACKGROUND: Presently, antibody concentration measurements for patients undergoing treatment are predominantly determined by ELISA, which still comes with known disadvantages. Therefore, our aim was to establish a targeted mass-spectrometric assay enabling the reproducible absolute quantification of peptides from the hypervariable and interaction regions of infliximab. METHODS: Peptides of infliximab were measured post-trypsin digestion and subsequent separation on a Vanquish Horizon UHPLC coupled to a TSQ Altis Triple-Quad mass spectrometer...
February 29, 2024: Clinical Proteomics
https://read.qxmd.com/read/38402394/proteomic-insights-into-the-pathophysiology-of-hypertension-associated-albuminuria-pilot-study-in-a-south-african-cohort
#16
JOURNAL ARTICLE
Melanie A Govender, Stoyan H Stoychev, Jean-Tristan Brandenburg, Michèle Ramsay, June Fabian, Ireshyn S Govender
BACKGROUND: Hypertension is an important public health priority with a high prevalence in Africa. It is also an independent risk factor for kidney outcomes. We aimed to identify potential proteins and pathways involved in hypertension-associated albuminuria by assessing urinary proteomic profiles in black South African participants with combined hypertension and albuminuria compared to those who have neither condition. METHODS: The study included 24 South African cases with both hypertension and albuminuria and 49 control participants who had neither condition...
February 24, 2024: Clinical Proteomics
https://read.qxmd.com/read/38389064/recent-progress-in-mass-spectrometry-based-urinary-proteomics
#17
REVIEW
Neha Joshi, Kishore Garapati, Vivek Ghose, Richard K Kandasamy, Akhilesh Pandey
Serum or plasma is frequently utilized in biomedical research; however, its application is impeded by the requirement for invasive sample collection. The non-invasive nature of urine collection makes it an attractive alternative for disease characterization and biomarker discovery. Mass spectrometry-based protein profiling of urine has led to the discovery of several disease-associated biomarkers. Proteomic analysis of urine has not only been applied to disorders of the kidney and urinary bladder but also to conditions affecting distant organs because proteins excreted in the urine originate from multiple organs...
February 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38389054/lessons-learned-establishing-a-clia-equivalent-laboratory-for-targeted-mass-spectrometry-assays-navigating-the-transition-from-research-to-clinical-practice
#18
JOURNAL ARTICLE
Chia-Li Han, Chi-Ting Lai, Aaron James Reyes, Hao-Chin Yang, Jin-Ying Lu, Shyang-Rong Shih, Kuen-Yuan Chen, Andrew N Hoofnagle, Sung-Liang Yu, William Bocik, Tara Hiltke, Huan-Chi Chiu, Ching-Yi Wan, Henry Rodriguez, Victoria Zhang, Yu-Ju Chen
Mass spectrometry (MS) assays offer exceptional capabilities in high multiplexity, specificity, and throughput. As proteomics technologies continue advancements to identify new disease biomarkers, transition of these innovations from research settings to clinical applications becomes imperative. To meet the rigorous regulatory standards of clinical laboratories, development of a clinical protein MS assay necessitates adherence to stringent criteria. To illustrate the process, this project focused on using thyroglobulin (Tg) as a biomarker and an immuno-multiple reaction monitoring (iMRM) MS-based assay as a model for establishing a Clinical Laboratory Improvement Amendments (CLIA) compliant laboratory within the Centers of Genomic and Precision Medicine, National Taiwan University...
February 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38389037/kinome-and-phosphoproteome-reprogramming-underlies-the-aberrant-immune-responses-in-critically-ill-covid-19-patients
#19
JOURNAL ARTICLE
Tomonori Kaneko, Sally Ezra, Rober Abdo, Courtney Voss, Shanshan Zhong, Xuguang Liu, Owen Hovey, Marat Slessarev, Logan Robert Van Nynatten, Mingliang Ye, Douglas Fraser, Shawn Shun-Cheng Li
SARS-CoV-2 infection triggers extensive host immune reactions, leading to severe diseases in certain individuals. However, the molecular basis underlying the excessive yet non-productive immune responses in severe COVID-19 remains incompletely understood. In this study, we conducted a comprehensive analysis of the peripheral blood mononuclear cell (PBMC) proteome and phosphoproteome in sepsis patients positive or negative for SARS-CoV-2 infection, as well as healthy subjects, using quantitative mass spectrometry...
February 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38368345/comparison-of-early-changes-in-tear-film-protein-profiles-after-small-incision-lenticule-extraction-smile-and-femtosecond-lasik-fs-lasik-surgery
#20
JOURNAL ARTICLE
Petri Mäkinen, Janika Nättinen, Ulla Aapola, Juhani Pietilä, Hannu Uusitalo
BACKGROUND: Small incision lenticule extraction (SMILE) and femtosecond laser-assisted in situ keratomileusis (LASIK) are widely used surgical methods to correct myopia with comparable efficacy, predictability, and safety. We examined and compared the early changes of tear protein profiles after SMILE and FS-LASIK surgery in order to find possible differences in the initial corneal healing process. METHODS: SMILE operations for 26 eyes were made with Visumax femtosecond laser...
February 17, 2024: Clinical Proteomics
journal
journal
40491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.